News | February 01, 2021
Sun Pharmaceutical Q3FY21 net profit at Rs. 1852.48 Cr
The company has reported total income of Rs.25699.68 crores during the 9 months period ended December 31, 2020.
The company has reported total income of Rs.25699.68 crores during the 9 months period ended December 31, 2020.
Post approval under the PLI scheme, Aurobindo will become a very large player in anti-biotic space.
The company is expecting tremendous growth and a better quarterly performance
Strides Pharma Science Limited is pleased to announce that Aditya Puri joins the Strides Group as an Advisor and also will be a Director of its associate Company, Stelis Biopharma.
The company was awarded the insulins supply contract for a three-year period in 2022 through April 2025
Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30%
Certification bolsters Venus Remedies' position in PIC/S markets, reinforcing commitment to global quality standards
3SBio will receive an upfront payment of $1.25 billion and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8 billion
This global affiliation marks a critical step in the company’s mission to create long-term value through ethical practices, scientific innovation, and inclusive healthcare delivery
Lupin is set to become first Indian company to fully integrate Honeywell’s Solstice® Air in its respiratory inhalers at scale, redefining respiratory care with near-zero global warming potential propellants
Subscribe To Our Newsletter & Stay Updated
